Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06649708
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-03
Brief Title:
HX044FIH Study in Patients With Advanced Solid Tumor Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IIIa First-in-Human Study Evaluating the Safety Tolerability Pharmacokinetics and Initial Efficacy of HX044 in Patients With Advanced Solid Tumor Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose MTD andor recommended Phase 2 dose RP2D and to evaluate the preliminary antitumor activity of HX044
HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration FDA or any other regulatory authorities for commercial purposes This is the first study in which HX044 will be given to humans The study drug has been tested in animals and was found to be well-tolerated with minimal side effects
HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration FDA or any other regulatory authorities for commercial purposes This is the first study in which HX044 will be given to humans The study drug has been tested in animals and was found to be well-tolerated with minimal side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None